# VAC 072-An Efficacy Study of R21/MM in Different Dose Schedules

> **NCT03970993** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Oxford** · enrollment: 78 (actual)

## Conditions studied

- Malaria

## Interventions

- **BIOLOGICAL:** R21 Matrix-M vaccination
- **BIOLOGICAL:** R21 Matrix-M vaccination and CHMI
- **BIOLOGICAL:** R21 Matrix-M vaccination booster

## Key facts

- **NCT ID:** NCT03970993
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-17
- **Primary completion:** 2021-08-24
- **Final completion:** 2021-08-24
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2021-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03970993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03970993, "VAC 072-An Efficacy Study of R21/MM in Different Dose Schedules". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03970993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*